skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreProduct loginProductLogin
Global Search Configuration

Recent months have seen a remarkable convergence of initiatives to foster greater European cooperation in market access. On the one hand, the EU has been promoting measures to expedite the launch of new medicines (eg adaptive pathways) and facilitate joint activity in health technology assessment. On the other hand, concerns over the pricing of some new drugs – most notably Gilead’s Sovaldi (sofosbuvir) – have prompted national governments to seek new alliances in order to help control the cost of innovative medicines. Whilst international collaboration in market access has undeniable attractions, it’s important to understand the recent changes thoroughly, especially in terms of the challenges such collaborations are likely to present in practice.

 

Our latest report provides an in-depth analysis into the recent key developments in the pharmaceutical market access environment and today, we are offering you a complimentary extract of this exclusive report.

 

This sample extract will provide you with an overview of our latest report ‘Key Trends in European Market Access’ which reviews in-depth the key developments in the pharmaceutical market access environment

Highlights in this report include:

  • Pros and cons of adaptive pathways for pharmaceutical manufacturers
  • European initiatives to harmonize health technology assessment (HTA)
  • Recent national HTA and reimbursement policies in Europe
  • Italy: Key measures and potential impact of the Health Pact on the pharmaceutical industry
  • Germany and France: The managed entry environment
  • Price resistance: Sovaldi case study
Sample-pages-Key-Trends-in-the-EU-market
Download whitepaper

Read also

  • Biomedtracker: see the drug development process through anal...

    Key Potential Drug Launches in 2022

    Released July 22, 2021. Contains information like likelihood of approval (LOA) ratings and upcoming catalysts that are current as of April 2021.

    Single Report

  • Biomedtracker: see the drug development process through anal...

    2020 Deal-Making Roundup

    Against a backdrop of unprecedented disruption, the biopharma and medtech industries reached incredible heights for deal-making activity during 2020.

    Topics Drug Review Coronavirus

    View white paper

  • Datamonitor Healthcare: data analysis and insight, Biomedtra...

    2021 Post-ASCO Insights and Analysis

    The American Society of Clinical Oncology (ASCO) hosted its annual meeting from June 4-8 2021 and our team has the exclusive insights and analysis you can access today.

    Topics Cancer

    Single Report
;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact Sales

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Contact Customer Services

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now